19/12/2022 Recombinant blood products for prophylaxis and management of haemophilia A and B
The Ministry of Health’s Drug Advisory Committee has recommended the following recombinant b...
The Ministry of Health’s Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:
Blood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.
The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.
Select a brand starting with the letter:
Please select a product for clinical info:
Please select a Registered Product for product info.